Quad's in it for antiretroviral therapy?

Affiliations

¹ Division of Molecular Medicine, Katholieke Universiteit Leuven, 3000 Leuven, Flanders, Belgium.
² Division of Molecular Medicine, Katholieke Universiteit Leuven, 3000 Leuven, Flanders, Belgium. Electronic address: zeger.debyser@med.kuleuven.be.

Comment

Rik Schrijvers et al. Lancet. 2012.

. 2012 Jun 30;379(9835):2403-2405.

doi: 10.1016/S0140-6736(12)61029-0.

¹ Division of Molecular Medicine, Katholieke Universiteit Leuven, 3000 Leuven, Flanders, Belgium.
² Division of Molecular Medicine, Katholieke Universiteit Leuven, 3000 Leuven, Flanders, Belgium. Electronic address: zeger.debyser@med.kuleuven.be.

No abstract available

Comment on

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial.
DeJesus E, Rockstroh JK, Henry K, Molina JM, Gathe J, Ramanathan S, Wei X, Yale K, Szwarcberg J, White K, Cheng AK, Kearney BP; GS-236-0103 Study Team. DeJesus E, et al. Lancet. 2012 Jun 30;379(9835):2429-2438. doi: 10.1016/S0140-6736(12)60918-0. Lancet. 2012. PMID: 22748590 Clinical Trial.
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.
Sax PE, DeJesus E, Mills A, Zolopa A, Cohen C, Wohl D, Gallant JE, Liu HC, Zhong L, Yale K, White K, Kearney BP, Szwarcberg J, Quirk E, Cheng AK; GS-US-236-0102 study team. Sax PE, et al. Lancet. 2012 Jun 30;379(9835):2439-2448. doi: 10.1016/S0140-6736(12)60917-9. Lancet. 2012. PMID: 22748591 Clinical Trial.